The kidney-targeted sodium-glucose cotransporter 2 (SGLT2) inhibitors Canagliflozin (Cana), Empagliflozin (Empa), and Dapagliflozin (Dapa) exhibited pronounced beneficial effects on cardiovascular outcome in patients with and without T2DM, including reductions in heart failure events, hospital admissions, and chronic kidney disease [12–15]. The gene discussed is SLC5A2; the disease is chronic kidney disease.